The BTN1A1 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population generated from the human LoVo colorectal adenocarcinoma cell line, featuring targeted disruption of the BTN1A1 gene. This loss-of-function model provides a powerful tool for investigating the immunomodulatory functions of butyrophilin subfamily 1 member A1 (BTN1A1), particularly its role in T cell inhibition and immune evasion. The polyclonal nature of the knockout pool reflects a heterogeneous mixture of edited alleles, enabling robust and reproducible studies without clonal selection biases.
The LoVo cell line was originally established from a metastatic lymph node of a male patient with colon adenocarcinoma and serves as a well-characterized in vitro model of colorectal cancer. These epithelial cells retain key features of the original tumor, including mutations relevant to colorectal carcinogenesis, and are widely employed in cancer biology research, drug sensitivity testing, and tumor immunology assays. Their colorectal adenocarcinoma origin makes them particularly suitable for studying the intersection of tumor cell immunomodulation and the tumor microenvironment.
BTN1A1 functions as an immune checkpoint molecule that, upon engagement with its cognate receptor, recruits the adaptor protein TYROBP (DAP12) to the plasma membrane. This interaction triggers a signaling cascade that suppresses T cell receptor (TCR) signaling by inhibiting the phosphorylation of the downstream kinases ZAP70 and LCK, thereby attenuating T cell activation and effector functions such as cytokine production. The expression and activity of BTN1A1 are regulated by upstream inflammatory cues, notably interferon-gamma (IFNG) signaling and other cytokine stimuli, positioning BTN1A1 as a link between the tumor inflammatory milieu and adaptive immune suppression. Consequently, BTN1A1 modulates key nodes within the TCR signaling and DAP12 signaling pathways, ultimately reducing T cell responses.
In the context of LoVo colorectal cancer cells, BTN1A1 knockout provides a unique opportunity to dissect how tumor-intrinsic immune checkpoint proteins contribute to local immune escape. By eliminating BTN1A1, researchers can directly assess the impact on T cell mediated anti-tumor immunity, such as restoration of T cell proliferation, IL-2 production, and effector functions in co-culture systems. This model is invaluable for validating BTN1A1 as a potential therapeutic target and for distinguishing its role from other known immune checkpoints like PD-L1. Furthermore, it allows exploration of BTN1A1-dependent signaling crosstalk within the tumor microenvironment at a molecular level.
BTN1A1 Knockout LoVo Polyclonal Cells enable diverse immunological and pharmacological studies. They are ideal for T cell activation assays measuring restored ZAP70/LCK phosphorylation and cytokine release via Western blotting or flow cytometry. Co-culture with T cells elucidates immune checkpoint mechanisms. High-throughput screening for BTN1A1 inhibitors or antibodies, along with in vivo xenograft models assessing tumor immunity, are key applications. Additional assays include co-immunoprecipitation with DAP12, RT-qPCR, and flow cytometry. For additional information, contact Ascent Research.
